Current state of tumour necrosis factor α blockade in Wegener's granulomatosis

Mukhtyar, C. ORCID: and Luqmani, R. (2005) Current state of tumour necrosis factor α blockade in Wegener's granulomatosis. Annals of the Rheumatic Diseases, 64 (SUPPL. 4). iv31-iv36. ISSN 0003-4967

Full text not available from this repository.


Tumour necrosis factor α (TNFα) is likely to be involved in the pathogenesis of Wegener's granulomatosis. This paper reviews published clinical trials of the anti-TNFα agents etonercept and infliximab with regard to their efficacy and safety in the treatment of Wegener's granulomatosis. On the basis of the high rate of adverse events, particularly an increased incidence of cancers, the use of etonercept in the management of Wegener's granulomatosis is not justified. However, the potential role for infliximab or the as yet untested adalimumab cannot be discounted. The development of novel approaches focusing on blockade of specific molecules including TNFα in the treatment of Wegener's granulomatosis is awaited.

Item Type: Article
Uncontrolled Keywords: immunology and allergy,rheumatology,immunology,biochemistry, genetics and molecular biology(all),sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2723
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 05 Jun 2020 00:02
Last Modified: 22 Oct 2022 06:16
DOI: 10.1136/ard.2005.042416

Actions (login required)

View Item View Item